CoLucid Hopes Lasmiditan Can Offer New, Safer Migraine Drug Class

07 Sep 2016

• By Sten Stovall

Prospects that CoLucid Pharmaceuticals’ lead asset might offer a viable new class of migraine treatment are brighter following the release of positive Phase III data showing lasmiditan helps twice as many patients to be headache-free after two hours versus a placebo.

CoLucid Pharmaceuticals Inc.'s share price surged after the Cambridge, Mass.-based company announced positive topline results from the SAMURAI Phase III study, the first of two pivotal studies evaluating oral lasmiditan, its lead asset, as an acute treatment for migraines.

The stock opened 83% higher Sept

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Multiple Launches Help Lilly’s Japan Growth

15 May 2025

• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Lundbeck Lifted By Leap In Migraine Therapy Sales

14 May 2025

• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

13 May 2025

• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

08 May 2025

• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.